InVivo Therapeutics (NASDAQ:NVIV) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of InVivo Therapeutics (NASDAQ:NVIV – Get Free Report) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock. InVivo Therapeutics Price Performance InVivo Therapeutics has a 12-month low of $0.22 and a 12-month high of $2.40. The […]

Related Keywords

United States , ,Renaissance Technologies ,Vanguard Group Inc ,Invivo Therapeutics Holdings Corp ,Citadel Advisors ,Invivo Therapeutics Company Profile ,Invivo Therapeutics ,Get Free Report ,Vivo Therapeutics ,Sigma Advisers ,Sigma Investments ,Vivo Therapeutics Holdings ,Neuro Spinal Scaffold ,Invivo Therapeutics Daily ,Nasdaq Nviv ,Enviv ,Medical ,Initiated Coverage ,Stocknews Com ,